A.F.L.–A.G.C. Building Trades Welfare Plan v. Jazz Pharmaceuticals
unknown- Filed:
- 2020-07-31
Patents:7851506
Antitrust pay-for-delay action in S.D.N.Y. citing the ’506 patent and describing the Xyrem settlement-driven generic launch schedule.
Defendant
Jazz Pharmaceuticals
4 cases as defendant.
- Cases
- 4
- Active
- 1
- 3 closed
- Filed
- 2015–2020
- Top venue
- Pto Ptab
- 1 case
Also appears as a plaintiff in 5 cases → View as plaintiff
Filing activity
(class action) v. Jazz Pharmaceuticals
related to MDL- Docket:
- 3:20-cv-04667
- Court:
- N.D. Cal.
- Filed:
- 2020-07-13
Patents:8263650
Class action related to the Xyrem MDL.
Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals
Final Written Decision- Docket:
- IPR2015-00554
- Court:
- USPTO PTAB
- Filed:
- 2015-01-08
Patents:7668730
Inter partes review petition filed by Par Pharmaceutical against US 7,668,730. The PTAB issued a Final Written Decision.
In re Xyrem (Sodium Oxybate) Antitrust Litigation
ongoing; trial set May 19, 2025; settlements with Amneal and Lupin final approval April 17, 2024Patents:8589182
Consolidated MDL antitrust litigation concerning Xyrem (sodium oxybate). U.S. 8,589,182 is listed among the patents cited/at issue. Class certification and summary-judgment motions have been decided; trial set for May 19, 2025.